Minerva Imaging

Welcoming William (“Bill”) Barbo to the Minerva Imaging Board of Directors. We are pleased to announce that Bill Barbo joined Minerva Imaging's Board of Directors on 4 September 2026. Bill is a global CRO executive with more than 30 years of leadership experience. In senior executive roles at Charles River Laboratories, including Executive Vice President and Chief Commercial Officer, he built and led international commercial organizations and supported drug development clients across global markets. He currently serves as an independent executive consultant and advisor to life science companies. As Minerva continues to expand its integrated CRO and CDMO platform for targeted radiopharmaceuticals, Bill's global CRO perspective, commercial leadership, and experience scaling client-focused organizations will be an important asset to Minerva Imaging. “Minerva has built a unique combination of scientific expertise and integrated radiopharmaceutical capabilities. I am excited to contribute to the company's next phase of growth and innovation”, said Bill Barbo. Read the full press release here: https://lnkd.in/eMTeaZWx Please join us in welcoming Bill to Minerva Imaging! #Radiopharmaceuticals #DrugDevelopment #CRO #CDMO #BoardOfDirectors #LifeSciences

This month, we gathered for the third Minerva Culture Day, an inspiring day filled with engaging talks, discussions on future initiatives, a poster session showcasing a wide range of internal projects as well as a run around the beautiful town of Helsingør. The event was a great opportunity to connect with our colleagues, learn more about our shared values and ambitions, and celebrate the diversity of backgrounds, perspectives, and experiences that make Minerva Imaging a welcoming and inclusive place to work. A special thank you to the organizers, speakers, and to everyone who participated and made this Culture Day another memorable event! #CultureDay #TeamBonding #TeamSpirit #DrugDevelopment #Radiopharmaceuticals

In a few weeks, we are heading to the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna. We are very much looking forward to meeting with key scientists and industry leaders, sharing insights into the latest developments in the nuclear medicines field.   Drop by our booth #521 to learn more about our fully integrated CRO/CMC/CDMO facility specializing in targeted radionuclide therapy and molecular imaging.   Want to delve deeper into our full-service offering from bench to bedside and discuss potential collaborations? We have setup a calendar for meeting bookings: https://lnkd.in/eYruQkid   #EANM26 #molecularimaging #radiopharmaceuticals #theranostics, #nuclearmedicine #radioligandtherapy #oncology #CRO #CMC #CDMO

The Göttingen minipig is emerging as a highly valuable model for radiopharmaceutical dosimetry, helping bridge the gap between preclinical studies and clinical translation. We are proud to have supported the Precirix team in this important study evaluating the biodistribution kinetics and dosimetry of radiolabeled 4AH29, a FAP-targeting single-domain antibody, in Göttingen minipigs. As part of the project, Minerva Imaging conducted the in vivo phase of the study, including dosing, imaging, sample collection, data analysis, and dosimetry calculations. Together, these data provided valuable insights into the biodistribution and radiation exposure profile of 4AH29, supporting its further development. Congratulations to all the authors! To learn more about this exciting study, please visit: https://lnkd.in/efFNqKuH At Minerva Imaging, we can support every step of your radiopharmaceutical program - from early target validation, radiolabeling, imaging to long-term toxicity follow-up and clinically relevant dosimetry reporting. If you are planning a dosimetry study, we would love to connect. Contact us at BD@minervaimaging.com.   #targetedradionuclidetherapy #dosimetry #FAP #molecularimaging #radiopharmaceuticals #drugdevelopment 

Heterogeneous responses to radiotherapy and immune checkpoint inhibition across different preclinical tumor models highlight the need to better understand the mechanisms of efficacy and resistance. Last Friday, Sarah from our MI scholar program, successfully defended her Master's thesis under the supervision of Jennifer, Senior Scientist, and Noemi, Scientist at Minerva Imaging, and Geert Berx, Professor at Ghent University. In her research, Sarah evaluated how different syngeneic tumor models respond to radiotherapy alone and in combination with immune checkpoint inhibition, followed by immunohistochemical and flow cytometry analysis to characterize treatment-induced changes in the tumor microenvironment. Her findings support an integrated approach that combines efficacy assessment with tumor microenvironment analysis to better understand the biological mechanisms of resistance and highlight the importance of tumor model selection in preclinical studies. Congratulations, Sarah! Great work! At Minerva Imaging, we continuously expand our portfolio of preclinical models and treatment modalities to support the development of next-generation radiopharmaceuticals and cancer therapies from bench to bedside. Are you planning a combination study in a syngeneic model? Contact us at BD@minervaimaging.com to start the discussion.   #MIscholar #masterthesis #oncology #immunotherapy #combinationtherapy #syngeneicmodels #radioimmunotherapy #radiotherapy 

Last Friday, we took part in the 45th edition of the DHL Relay in Copenhagen, one of the world's largest corporate sporting events. This year's event brought together more than 160,000 participants from over 2,500 companies. Despite the gloomy weather, our teams showed great energy, team spirit, and determination as they completed the 5 km route through the beautiful Fælledparken. We were proud to see 3 Minerva Imaging teams ranking among the top 10 performers in both the men’s and women’s Friday classifications! After crossing the finish line, we gathered for food, refreshments, and great conversations, a perfect way to celebrate teamwork, strengthen connections, and enjoy the evening together. A big thank you goes out to all our organizers, runners, and supporters who made this evening another memorable experience. #DHLRelay2026 #DHLStafet #Teamspirit #DHL2026

We're thrilled to welcome David Kroon to Minerva Imaging as our first General Manager, US. David brings more than 20 years of radiopharmaceutical experience - most recently as President of Rotem Inc., and before that in senior roles at PharmaLogic Holdings, GE Healthcare Life Sciences, and Lantheus Medical Imaging, where he built and led a global CMO network of 25 partners across six countries. Based in the greater Boston area, David will lead our US commercial expansion, build the founding US team, and support the strategic evaluation of a future US CDMO footprint - bringing Minerva's integrated CRO/CDMO capabilities closer to our US customers. "Our US sponsors are asking for an in-region partner who understands the technical, regulatory, and commercial realities of PET and targeted radionuclide therapy. David will be that partner." says Carsten Haagen Nielsen, Co-founder & CEO, Minerva Imaging Read the full press release here: https://lnkd.in/e7ijbwUi Welcome to the team, David. The next chapter starts now. #Radiopharmaceuticals #CDMO #TargetedRadionuclideTherapy #PET #MinervaImaging #Oncology

Welcome Signe Humle Jørgensen to Minerva Imaging! We are thrilled to announce that Signe Humle Jorgensen has joined Minerva Imaging as Head of CRO. Signe is a senior life science executive with more than two decades of experience across biotech, pharma and CRO environments. She has held senior leadership roles at CRO and pharmaceutical companies, with experience spanning drug discovery, preclinical development and clinical translation. Her expertise covers multiple therapeutic areas, with a strong focus on scientific leadership and cross-functional collaboration. At Minerva Imaging, Signe will lead the CRO organisation, supporting our collaborators with high-quality preclinical research and drug development, while working closely with colleagues across our CRO and internal R&D activities. We look forward to having Signe as part of the team! #radiopharmaceuticals #drugdevelopment #molecularimaging #CRO #CDMO #career 

Don’t let poor tumor delivery kill your ADC in Phase III. See it in Phase 0.   2025 brought 130+ new ADC candidates into the clinic, but this year alone we’ve watched high-profile Phase III reads miss. Toxicity gets most of the attention. But a quieter, mechanistic problem repeats across the discontinued-ADC literature: insufficient efficacy at the tolerated dose, the signature of an antibody that never reached enough of the tumor to be effective. The “binding site barrier” traps large, high-affinity antibodies near tumor vasculature before they can penetrate deeper into the tissue. Preclinical ImmunoPET studies have show tumor uptake predicting ADC response, but IHC does not correlate. At Minerva Imaging, we radiolabel and image antibodies and ADCs to evaluate tumor uptake. Our expertise ranges from early ⁸⁹Zr/⁶⁴Cu biodistribution studies through GMP clinical dose supply to help answer one question before your pivotal trial is designed: does your antibody actually get where it needs to go? We wrote up the evidence and our thinking in a short position paper. If your team is heading into IND-enabling work on an ADC or complex biologic, we’d welcome the chance to compare notes. Contact us at BD@minervaimaging.com and we will get in touch. #ADC #Antibody #Radiopharmaceuticals #MolecularImaging #Oncology #DrugDevelopment #ImmunoPET #Biotech

Minerva Imaging and TD2 Oncology partner to expand radiopharmaceutical development support.   We are proud to announce a strategic collaboration with TD2 Oncology, combining our expertise in targeted radiopharmaceutical development, molecular imaging, and manufacturing with TD2 Oncology’s strengths in translational, regulatory, and clinical drug development. Together, we aim to provide sponsors with a seamless path to advance radioligand therapy programs from discovery to clinical trials more efficiently and rapidly.   Carsten, CEO and co-founder of Minerva Imaging, said: ‘’Sponsors need a partner who can move at the pace their science demands, without compromising quality or compliance. Our focus is on supporting our customers with a fast, de-risked transition into the clinic – providing radiochemistry and clinical dose supply they need, when they need it. Working alongside TD2 Oncology, in the US we can give sponsors a single, coordinated path from translational research to first patients dosed.’’   Read the full press release here: https://lnkd.in/eNjQxqk3   Reach out at BD@minervaimaging.com if you want to discuss how we can support your radiopharmaceutical program from concept to clinical dose supply.   #Radiopharmaceuticals #RadioligandTherapy #MolecularImaging #DrugDevelopment #ClinicalTrials #Oncology #PrecisionMedicine #Partnership